Unlike most of the compounds on this site, these two are FDA-approved prescription medications, not research-use-only compounds. That’s worth stating plainly before comparing how they work.
Want something built around your specific situation, not general reading? PeptideReport.ai turns a short guided intake into a free, personalized educational report you can actually bring to your doctor — and registering gets you The Peptide Bridge audiobook free, a $29.99 value, delivered to your inbox right away.
Get my free report + free book →Most peptides covered on this site — BPC-157, the GH-axis compounds, the nootropic peptides — are research-use-only and have not completed FDA's approval process. Semaglutide and tirzepatide are different: both are FDA-approved medications, available by prescription, manufactured under pharmaceutical quality standards, and backed by large-scale clinical trial data. Treating them as part of the same "research peptide" conversation as an RUO compound understates how different their regulatory and evidence status actually is. See our legal status guide for the full three-tier breakdown.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism class | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Receptor targets | One receptor (GLP-1) | Two receptors (GLP-1 and GIP) |
| Regulatory status | FDA-approved, brand-name prescription products | FDA-approved, brand-name prescription products |
| Approval basis | Multiple completed Phase 3 trial programs across approved indications | Multiple completed Phase 3 trial programs across approved indications |
Both drugs work on the GLP-1 receptor, part of the body's natural system for regulating appetite and blood sugar after eating. Tirzepatide adds a second target — the GIP receptor — which is a separate but related hormone pathway. That dual-receptor mechanism is the core scientific distinction between the two drugs, and it's the basis for the clinical trials that compared their effects head-to-head.
Because these two are real prescription drugs with real trial data, it's tempting to assume research-use-only compounds marketed as "similar" mechanisms carry similar evidence. They don't. An RUO compound described as working on "the same pathway" as semaglutide has not been through anything resembling the clinical trial process these two drugs completed. See our myths page for more on this specific confusion.
Both compounds have entries on the compounds reference page. For what a real prescribing relationship for either of these looks like, see talking to your doctor. For more comparisons, see the comparisons hub.
Reading about this by name is a starting point, not a plan. PeptideReport.ai turns general reading like this into a free, personalized report you can bring to a licensed physician — the person actually qualified to weigh these considerations against your health history.
Get your free report at PeptideReport.ai →
Free bonus: register today and The Peptide Bridge audiobook — a physician-authored, plain-English guide to peptide therapy, a $29.99 value — is yours free, delivered to your inbox right away.